speb/financial-data huggingface dataset:
RWT income_statement (quarterly, 2026-03-31) — +Total Revenue: 48477000.00
RWT balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 116807000.00
RWT balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 143415000.00
RWT balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -15000000.00
RWT balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 2468269000.00
RWT balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 266638000.00
RWT income_statement (quarterly, 2026-03-31) — Average Dilution Earnings: -1256000.00
RWT income_statement (quarterly, 2026-03-31) — Basic Average Shares: 124769000.00
RWT income_statement (quarterly, 2026-03-31) — Basic EPS: -0.07
RWT cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 449110000.00
RWT balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 9713000.00
RWT balance_sheet (quarterly, 2026-03-31) — Capital Stock: 68198000.00
RWT balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 202414000.00
RWT balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Federal Funds Sold: 294699000.00
RWT cash_flow (quarterly, 2026-03-31) — Cash Dividends Paid: -25505000.00
RWT cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 3124417000.00
RWT cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: 1228763000.00
RWT cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -4507591000.00
RWT cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: 18777000.00
RWT cash_flow (quarterly, 2026-03-31) — Change In Other Current Assets: -83317000.00
RWT cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: 18777000.00
RWT cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -64540000.00
RWT cash_flow (quarterly, 2026-03-31) — Changes In Cash: -154411000.00
RWT balance_sheet (quarterly, 2026-03-31) — Common Stock: 1250000.00
RWT cash_flow (quarterly, 2026-03-31) — Common Stock Dividend Paid: -23755000.00
RWT balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 889763000.00
RWT cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 97000.00
RWT cash_flow (quarterly, 2026-03-31) — Common Stock Payments: -1118000.00
RWT balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 14982000.00
RWT balance_sheet (quarterly, 2026-03-31) — Current Debt: 3251160000.00
RWT balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 3251160000.00
RWT cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 2272000.00
RWT cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 2272000.00
RWT balance_sheet (quarterly, 2026-03-31) — Derivative Product Liabilities: 156244000.00
RWT income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 124769000.00
RWT income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.07
RWT income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -8509000.00
RWT balance_sheet (quarterly, 2026-03-31) — Dividends Payable: 1478000.00
RWT balance_sheet (quarterly, 2026-03-31) — Employee Benefits: 19477000.00
RWT cash_flow (quarterly, 2026-03-31) — End Cash Position: 294699000.00
RWT cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 3124417000.00
RWT cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -4507591000.00
RWT cash_flow (quarterly, 2026-03-31) — Gain Loss On Investment Securities: 0.00
RWT income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: -16090000.00
RWT balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: -31367000.00
RWT income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 47425000.00
RWT balance_sheet (quarterly, 2026-03-31) — Goodwill: 23373000.00
RWT balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 111759000.00
RWT balance_sheet (quarterly, 2026-03-31) — Gross PPE: 31059000.00
RWT cash_flow (quarterly, 2026-03-31) — Income Tax Paid Supplemental Data: 0.00
RWT balance_sheet (quarterly, 2026-03-31) — Income Tax Payable: 0.00
RWT income_statement (quarterly, 2026-03-31) — Interest Expense: 322202000.00
RWT income_statement (quarterly, 2026-03-31) — Interest Income: 356919000.00
RWT cash_flow (quarterly, 2026-03-31) — Interest Paid Supplemental Data: 298473000.00
RWT balance_sheet (quarterly, 2026-03-31) — Invested Capital: 25931565000.00
RWT cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: 1228763000.00
RWT balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 803038000.00
RWT cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 97000.00
RWT cash_flow (quarterly, 2026-03-31) — Issuance Of Debt: 11664203000.00
RWT balance_sheet (quarterly, 2026-03-31) — Line Of Credit: 3116188000.00
RWT balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 9713000.00
RWT balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 21790642000.00
RWT balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 21800355000.00
RWT cash_flow (quarterly, 2026-03-31) — Long Term Debt Issuance: 11664203000.00
RWT cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -8507177000.00
RWT balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 60013000.00
RWT balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 5650000.00
RWT cash_flow (quarterly, 2026-03-31) — Net Business Purchase And Sale: 1314000.00
RWT cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: -1021000.00
RWT balance_sheet (quarterly, 2026-03-31) — Net Debt: 24839388000.00
RWT income_statement (quarterly, 2026-03-31) — Net Income: -5503000.00
RWT income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -7253000.00
RWT income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -5503000.00
RWT income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -5503000.00
RWT income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -5503000.00
RWT cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -5503000.00
RWT income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -5503000.00
RWT income_statement (quarterly, 2026-03-31) — Net Interest Income: 34717000.00
RWT cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: -10431000.00
RWT cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: 3157026000.00
RWT cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: 3157026000.00
RWT cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -6083000.00
RWT cash_flow (quarterly, 2026-03-31) — Net Other Investing Changes: -735000.00
RWT balance_sheet (quarterly, 2026-03-31) — Net PPE: 16059000.00
RWT balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 844952000.00
RWT balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 14304000.00
RWT balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Revenue: 14304000.00
RWT income_statement (quarterly, 2026-03-31) — Normalized Income: -5503000.00
RWT cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -4507591000.00
RWT cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: -7338000.00
RWT income_statement (quarterly, 2026-03-31) — Operating Revenue: 48477000.00
RWT balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 125015499.00
RWT balance_sheet (quarterly, 2026-03-31) — Other Current Borrowings: 134972000.00
RWT balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: -31367000.00
RWT income_statement (quarterly, 2026-03-31) — Other Gand A: 11452000.00
RWT balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 88386000.00
RWT cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: -4441554000.00
RWT income_statement (quarterly, 2026-03-31) — Other Non Interest Expense: 7125000.00
RWT balance_sheet (quarterly, 2026-03-31) — Other Payable: 45360000.00
RWT balance_sheet (quarterly, 2026-03-31) — Other Properties: 31059000.00
RWT balance_sheet (quarterly, 2026-03-31) — Other Receivables: 127992000.00
RWT balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 294250000.00
RWT balance_sheet (quarterly, 2026-03-31) — Payables: 287205000.00
RWT balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 302187000.00
RWT balance_sheet (quarterly, 2026-03-31) — Preferred Securities Outside Stock Equity: 138917000.00
RWT balance_sheet (quarterly, 2026-03-31) — Preferred Shares Number: 2800000.00
RWT balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 66948000.00
RWT cash_flow (quarterly, 2026-03-31) — Preferred Stock Dividend Paid: -1750000.00
RWT income_statement (quarterly, 2026-03-31) — Preferred Stock Dividends: 1750000.00
RWT balance_sheet (quarterly, 2026-03-31) — Preferred Stock Equity: 66948000.00
RWT income_statement (quarterly, 2026-03-31) — Pretax Income: -8006000.00
RWT income_statement (quarterly, 2026-03-31) — Professional Expense And Contract Services Expense: 1933000.00
RWT cash_flow (quarterly, 2026-03-31) — Purchase Of Business: -2612000.00
RWT cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: -54791000.00
RWT balance_sheet (quarterly, 2026-03-31) — Receivables: 302711000.00
RWT income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 2272000.00
RWT cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -8507177000.00
RWT cash_flow (quarterly, 2026-03-31) — Repurchase Of Capital Stock: -1118000.00
RWT balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -1548389000.00
RWT income_statement (quarterly, 2026-03-31) — Salaries And Wages: 35973000.00
RWT cash_flow (quarterly, 2026-03-31) — Sale Of Business: 3926000.00
RWT cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 44360000.00
RWT income_statement (quarterly, 2026-03-31) — Selling General And Administration: 47425000.00
RWT balance_sheet (quarterly, 2026-03-31) — Share Issued: 125015499.00
RWT cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 6215000.00
RWT balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 956711000.00
RWT balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 778004000.00
RWT income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
RWT income_statement (quarterly, 2026-03-31) — Tax Provision: -2503000.00
RWT income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.31
RWT balance_sheet (quarterly, 2026-03-31) — Total Assets: 26815797000.00
RWT balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 22747353000.00
RWT balance_sheet (quarterly, 2026-03-31) — Total Debt: 25051515000.00
RWT balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 956711000.00
RWT balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 25859086000.00
RWT balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 0.00
RWT balance_sheet (quarterly, 2026-03-31) — Trading Securities: 182137000.00
RX.V cash_flow (annual, 2021-12-31) — Gain Loss On Investment Securities: -78608.00
RX.V cash_flow (annual, 2021-12-31) — Operating Gains Losses: -78608.00
RX.V income_statement (annual, 2021-12-31) — Other Non Operating Income Expenses: 125000.00
RX.V income_statement (annual, 2022-12-31) — +Operating Expense: 15951044.00
RX.V income_statement (annual, 2022-12-31) — +Total Revenue: 27925187.00
RX.V balance_sheet (annual, 2022-12-31) — Accounts Payable: 5062882.00
RX.V balance_sheet (annual, 2022-12-31) — Accounts Receivable: 2790905.00
RX.V balance_sheet (annual, 2022-12-31) — Accrued Interest Receivable: 389692.00
RX.V balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -1591042.00
RX.V balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 2228517.00
RX.V income_statement (annual, 2022-12-31) — Amortization: 145648.00
RX.V cash_flow (annual, 2022-12-31) — Amortization Cash Flow: 145648.00
RX.V cash_flow (annual, 2022-12-31) — Amortization Of Intangibles: 145648.00
RX.V income_statement (annual, 2022-12-31) — Amortization Of Intangibles Income Statement: 145648.00
RX.V cash_flow (annual, 2022-12-31) — Asset Impairment Charge: 106000.00
RX.V income_statement (annual, 2022-12-31) — Basic Average Shares: 12303121.00
RX.V income_statement (annual, 2022-12-31) — Basic EPS: 0.44
RX.V cash_flow (annual, 2022-12-31) — Beginning Cash Position: 18035275.00
RX.V balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 1330455.00
RX.V cash_flow (annual, 2022-12-31) — Capital Expenditure: -519317.00
RX.V balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 1395100.00
RX.V balance_sheet (annual, 2022-12-31) — Capital Stock: 5367432.00
RX.V balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 7864559.00
RX.V balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 28695644.00
RX.V cash_flow (annual, 2022-12-31) — Cash Dividends Paid: -483958.00
RX.V balance_sheet (annual, 2022-12-31) — Cash Equivalents: 2566243.00
RX.V balance_sheet (annual, 2022-12-31) — Cash Financial: 5298316.00
RX.V cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: -4371489.00
RX.V cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -10790099.00
RX.V cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: 4948756.00
RX.V cash_flow (annual, 2022-12-31) — Change In Account Payable: 1499748.00
RX.V cash_flow (annual, 2022-12-31) — Change In Income Tax Payable: 219314.00
RX.V cash_flow (annual, 2022-12-31) — Change In Inventory: -2437012.00
RX.V cash_flow (annual, 2022-12-31) — Change In Other Working Capital: -149260.00
RX.V cash_flow (annual, 2022-12-31) — Change In Payable: 1719062.00
RX.V cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: 1719062.00
RX.V cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: 201076.00
RX.V cash_flow (annual, 2022-12-31) — Change In Receivables: -426373.00
RX.V cash_flow (annual, 2022-12-31) — Change In Tax Payable: 219314.00
RX.V cash_flow (annual, 2022-12-31) — Change In Working Capital: -1092507.00
RX.V cash_flow (annual, 2022-12-31) — Changes In Cash: -10212832.00
RX.V balance_sheet (annual, 2022-12-31) — Common Stock: 5367432.00
RX.V cash_flow (annual, 2022-12-31) — Common Stock Dividend Paid: -483958.00
RX.V balance_sheet (annual, 2022-12-31) — Common Stock Equity: 33362523.00
RX.V cash_flow (annual, 2022-12-31) — Common Stock Payments: -3688657.00
RX.V income_statement (annual, 2022-12-31) — Cost Of Revenue: 5067304.00
RX.V balance_sheet (annual, 2022-12-31) — Current Assets: 37142829.00
RX.V balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 174055.00
RX.V balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 174055.00
RX.V balance_sheet (annual, 2022-12-31) — Current Deferred Liabilities: 164372.00
RX.V balance_sheet (annual, 2022-12-31) — Current Deferred Revenue: 164372.00
RX.V balance_sheet (annual, 2022-12-31) — Current Liabilities: 5719314.00
RX.V cash_flow (annual, 2022-12-31) — Deferred Income Tax: -8844.00
RX.V cash_flow (annual, 2022-12-31) — Deferred Tax: -8844.00
RX.V cash_flow (annual, 2022-12-31) — Depreciation: 305350.00
RX.V cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 450998.00
RX.V income_statement (annual, 2022-12-31) — Depreciation Amortization Depletion Income Statement: 450998.00
RX.V cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 450998.00
RX.V income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 450998.00
RX.V income_statement (annual, 2022-12-31) — Depreciation Income Statement: 305350.00
RX.V income_statement (annual, 2022-12-31) — Diluted Average Shares: 12540638.00
RX.V income_statement (annual, 2022-12-31) — Diluted EPS: 0.44
RX.V income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: 5458345.00
RX.V income_statement (annual, 2022-12-31) — EBIT: 7507793.00
RX.V income_statement (annual, 2022-12-31) — EBITDA: 7958791.00
RX.V cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: 42116.00
RX.V cash_flow (annual, 2022-12-31) — End Cash Position: 7864559.00
RX.V cash_flow (annual, 2022-12-31) — Financing Cash Flow: -4371489.00
RX.V balance_sheet (annual, 2022-12-31) — Finished Goods: 3553946.00
RX.V balance_sheet (annual, 2022-12-31) — Foreign Currency Translation Adjustments: -143144.00
RX.V cash_flow (annual, 2022-12-31) — Free Cash Flow: 4429439.00
RX.V income_statement (annual, 2022-12-31) — Gain On Sale Of Security: 75159.00
RX.V balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: -143144.00
RX.V income_statement (annual, 2022-12-31) — General And Administrative Expense: 8810078.00
RX.V balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 1200878.00
RX.V balance_sheet (annual, 2022-12-31) — Gross PPE: 3264078.00
RX.V income_statement (annual, 2022-12-31) — Gross Profit: 22857883.00
RX.V balance_sheet (annual, 2022-12-31) — Held To Maturity Securities: 0.00
RX.V cash_flow (annual, 2022-12-31) — Income Tax Paid Supplemental Data: 1761836.00
RX.V balance_sheet (annual, 2022-12-31) — Income Tax Payable: 318005.00
RX.V income_statement (annual, 2022-12-31) — Insurance And Claims: 168470.00
RX.V income_statement (annual, 2022-12-31) — Interest Expense: 77142.00
RX.V income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 77142.00
RX.V income_statement (annual, 2022-12-31) — Interest Income: 525795.00
RX.V income_statement (annual, 2022-12-31) — Interest Income Non Operating: 525795.00
RX.V cash_flow (annual, 2022-12-31) — Interest Paid Cff: -77142.00
RX.V cash_flow (annual, 2022-12-31) — Interest Received Cfi: 191149.00
RX.V balance_sheet (annual, 2022-12-31) — Inventory: 4535343.00
RX.V balance_sheet (annual, 2022-12-31) — Invested Capital: 33362523.00
RX.V cash_flow (annual, 2022-12-31) — Investing Cash Flow: -10790099.00
RX.V balance_sheet (annual, 2022-12-31) — Investmentin Financial Assets: 0.00
RX.V balance_sheet (annual, 2022-12-31) — Investments And Advances: 0.00
RX.V balance_sheet (annual, 2022-12-31) — Leases: 680511.00
RX.V balance_sheet (annual, 2022-12-31) — Loans Receivable: 158529.00
RX.V balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 1221045.00
RX.V balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 1221045.00
RX.V cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -161812.00
RX.V balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 1013107.00
RX.V cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: -3688657.00
RX.V income_statement (annual, 2022-12-31) — Net Income: 5458345.00
RX.V income_statement (annual, 2022-12-31) — Net Income Common Stockholders: 5458345.00
RX.V income_statement (annual, 2022-12-31) — Net Income Continuous Operations: 5458345.00
RX.V income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: 5458345.00
RX.V income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: 5458345.00
RX.V cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: 5458345.00
RX.V income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: 5458345.00
RX.V cash_flow (annual, 2022-12-31) — Net Intangibles Purchase And Sale: -472500.00
RX.V income_statement (annual, 2022-12-31) — Net Interest Income: 448653.00
RX.V cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: -10654690.00
RX.V cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -161812.00
RX.V cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -161812.00
RX.V income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: 448653.00
RX.V cash_flow (annual, 2022-12-31) — Net Other Investing Changes: 192759.00
RX.V balance_sheet (annual, 2022-12-31) — Net PPE: 1673036.00
RX.V cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -46817.00
RX.V balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 32161645.00
RX.V balance_sheet (annual, 2022-12-31) — Non Current Deferred Assets: 210281.00
RX.V balance_sheet (annual, 2022-12-31) — Non Current Deferred Liabilities: 182382.00
RX.V balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Assets: 210281.00
RX.V balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Liabilities: 182382.00
RX.V balance_sheet (annual, 2022-12-31) — Non Current Note Receivables: 258240.00
RX.V income_statement (annual, 2022-12-31) — Normalized EBITDA: 7883632.00
RX.V income_statement (annual, 2022-12-31) — Normalized Income: 5403135.34
RX.V cash_flow (annual, 2022-12-31) — Operating Cash Flow: 4948756.00
RX.V income_statement (annual, 2022-12-31) — Operating Income: 6906839.00
RX.V income_statement (annual, 2022-12-31) — Operating Revenue: 27925187.00
RX.V balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 12097861.00
RX.V income_statement (annual, 2022-12-31) — Other Gand A: 1228526.00
RX.V income_statement (annual, 2022-12-31) — Other Income Expense: 75159.00
RX.V balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 1200878.00
RX.V cash_flow (annual, 2022-12-31) — Other Non Cash Items: -348876.00
RX.V balance_sheet (annual, 2022-12-31) — Other Non Current Liabilities: 1403427.00
RX.V income_statement (annual, 2022-12-31) — Other Operating Expenses: 97474.00
RX.V balance_sheet (annual, 2022-12-31) — Other Properties: 240005.00
RX.V balance_sheet (annual, 2022-12-31) — Other Receivables: 317758.00
RX.V balance_sheet (annual, 2022-12-31) — Other Short Term Investments: 20831085.00
RX.V balance_sheet (annual, 2022-12-31) — Payables: 5380887.00
RX.V balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 5380887.00
RX.V balance_sheet (annual, 2022-12-31) — Prepaid Assets: 254958.00
RX.V income_statement (annual, 2022-12-31) — Pretax Income: 7430651.00
RX.V cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 40080.00
RX.V balance_sheet (annual, 2022-12-31) — Properties: 0.00
RX.V income_statement (annual, 2022-12-31) — Provision For Doubtful Accounts: 49969.00
RX.V cash_flow (annual, 2022-12-31) — Provisionand Write Offof Assets: 49969.00
RX.V cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: -472500.00
RX.V cash_flow (annual, 2022-12-31) — Purchase Of Investment: -10654690.00
RX.V cash_flow (annual, 2022-12-31) — Purchase Of PPE: -46817.00
RX.V balance_sheet (annual, 2022-12-31) — Raw Materials: 981397.00
RX.V balance_sheet (annual, 2022-12-31) — Receivables: 3656884.00
RX.V income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 5067304.00
RX.V income_statement (annual, 2022-12-31) — Reconciled Depreciation: 450998.00
RX.V cash_flow (annual, 2022-12-31) — Repayment Of Debt: -161812.00
RX.V cash_flow (annual, 2022-12-31) — Repurchase Of Capital Stock: -3688657.00
RX.V income_statement (annual, 2022-12-31) — Research And Development: 121025.00
RX.V balance_sheet (annual, 2022-12-31) — Retained Earnings: 25909718.00
RX.V income_statement (annual, 2022-12-31) — Salaries And Wages: 7413082.00
RX.V income_statement (annual, 2022-12-31) — Selling And Marketing Expense: 6421500.00
RX.V income_statement (annual, 2022-12-31) — Selling General And Administration: 15231578.00
RX.V balance_sheet (annual, 2022-12-31) — Share Issued: 12339161.00
RX.V cash_flow (annual, 2022-12-31) — Stock Based Compensation: 439671.00
RX.V balance_sheet (annual, 2022-12-31) — Stockholders Equity: 33362523.00
RX.V balance_sheet (annual, 2022-12-31) — Tangible Book Value: 32161645.00
RX.V income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 19949.34
RX.V income_statement (annual, 2022-12-31) — Tax Provision: 1972306.00
RX.V income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.27
RX.V balance_sheet (annual, 2022-12-31) — Taxes Receivable: 0.00
RX.V balance_sheet (annual, 2022-12-31) — Total Assets: 40485264.00
RX.V balance_sheet (annual, 2022-12-31) — Total Capitalization: 33362523.00
RX.V balance_sheet (annual, 2022-12-31) — Total Debt: 1395100.00
RX.V balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 33362523.00
RX.V income_statement (annual, 2022-12-31) — Total Expenses: 21018348.00
RX.V balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 7122741.00
RX.V balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 3342435.00
RX.V balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 1403427.00
RX.V income_statement (annual, 2022-12-31) — Total Operating Income As Reported: 6981998.00
RX.V balance_sheet (annual, 2022-12-31) — Total Tax Payable: 318005.00
RX.V income_statement (annual, 2022-12-31) — Total Unusual Items: 75159.00
RX.V income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: 75159.00
RX.V balance_sheet (annual, 2022-12-31) — Treasury Shares Number: 241300.00
RX.V balance_sheet (annual, 2022-12-31) — Working Capital: 31423515.00
RX.V income_statement (annual, 2023-12-31) — +Operating Expense: 18063689.00
RX.V income_statement (annual, 2023-12-31) — +Total Revenue: 31590302.00
RX.V balance_sheet (annual, 2023-12-31) — Accounts Payable: 5077676.00
RX.V balance_sheet (annual, 2023-12-31) — Accounts Receivable: 2797882.00
RX.V balance_sheet (annual, 2023-12-31) — Accrued Interest Receivable: 653885.00
RX.V balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -1883674.00
RX.V balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 2286934.00
RX.V income_statement (annual, 2023-12-31) — Amortization: 162706.00
RX.V cash_flow (annual, 2023-12-31) — Amortization Cash Flow: 162706.00
RX.V cash_flow (annual, 2023-12-31) — Amortization Of Intangibles: 162706.00
RX.V income_statement (annual, 2023-12-31) — Amortization Of Intangibles Income Statement: 162706.00
RX.V cash_flow (annual, 2023-12-31) — Asset Impairment Charge: 0.00
RX.V income_statement (annual, 2023-12-31) — Basic Average Shares: 11949895.00
RX.V income_statement (annual, 2023-12-31) — Basic EPS: 0.54
RX.V cash_flow (annual, 2023-12-31) — Beginning Cash Position: 7864559.00
RX.V balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 1330455.00
RX.V cash_flow (annual, 2023-12-31) — Capital Expenditure: -174230.00
RX.V balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 1221045.00
RX.V balance_sheet (annual, 2023-12-31) — Capital Stock: 5122350.00
RX.V balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 7984534.00
RX.V balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 26187011.00
RX.V cash_flow (annual, 2023-12-31) — Cash Dividends Paid: -1912835.00
RX.V balance_sheet (annual, 2023-12-31) — Cash Equivalents: 3078520.00
RX.V balance_sheet (annual, 2023-12-31) — Cash Financial: 4906014.00
RX.V cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: -5784535.00
RX.V cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: 883847.00
RX.V cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: 5054974.00
RX.V cash_flow (annual, 2023-12-31) — Change In Account Payable: 14794.00
RX.V cash_flow (annual, 2023-12-31) — Change In Income Tax Payable: -206891.00
RX.V cash_flow (annual, 2023-12-31) — Change In Inventory: -1481749.00
RX.V cash_flow (annual, 2023-12-31) — Change In Other Working Capital: -29911.00
RX.V cash_flow (annual, 2023-12-31) — Change In Payable: -192097.00
RX.V cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: -192097.00
RX.V cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: 11498.00
RX.V cash_flow (annual, 2023-12-31) — Change In Receivables: 241363.00
RX.V cash_flow (annual, 2023-12-31) — Change In Tax Payable: -206891.00
RX.V cash_flow (annual, 2023-12-31) — Change In Working Capital: -1450896.00
RX.V cash_flow (annual, 2023-12-31) — Changes In Cash: 154286.00
RX.V balance_sheet (annual, 2023-12-31) — Common Stock: 5122350.00
RX.V cash_flow (annual, 2023-12-31) — Common Stock Dividend Paid: -1912835.00
RX.V balance_sheet (annual, 2023-12-31) — Common Stock Equity: 34759756.00
RX.V cash_flow (annual, 2023-12-31) — Common Stock Payments: -3068899.00
RX.V income_statement (annual, 2023-12-31) — Cost Of Revenue: 5992359.00
RX.V balance_sheet (annual, 2023-12-31) — Current Assets: 35871481.00
RX.V balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 183314.00
RX.V balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 183314.00
RX.V balance_sheet (annual, 2023-12-31) — Current Deferred Liabilities: 134461.00
RX.V balance_sheet (annual, 2023-12-31) — Current Deferred Revenue: 134461.00
RX.V balance_sheet (annual, 2023-12-31) — Current Liabilities: 5533850.00
RX.V cash_flow (annual, 2023-12-31) — Deferred Income Tax: -133969.00
RX.V cash_flow (annual, 2023-12-31) — Deferred Tax: -133969.00
RX.V cash_flow (annual, 2023-12-31) — Depreciation: 292632.00
RX.V cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 455338.00
RX.V income_statement (annual, 2023-12-31) — Depreciation Amortization Depletion Income Statement: 455338.00
RX.V cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 455338.00
RX.V income_statement (annual, 2023-12-31) — Depreciation And Amortization In Income Statement: 455338.00
RX.V income_statement (annual, 2023-12-31) — Depreciation Income Statement: 292632.00
RX.V income_statement (annual, 2023-12-31) — Diluted Average Shares: 12170410.00
RX.V income_statement (annual, 2023-12-31) — Diluted EPS: 0.53
RX.V income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: 6460127.00
RX.V income_statement (annual, 2023-12-31) — EBIT: 8602264.00
RX.V income_statement (annual, 2023-12-31) — EBITDA: 9057602.00
RX.V cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: -34311.00
RX.V cash_flow (annual, 2023-12-31) — End Cash Position: 7984534.00
RX.V cash_flow (annual, 2023-12-31) — Financing Cash Flow: -5784535.00
RX.V balance_sheet (annual, 2023-12-31) — Finished Goods: 4624515.00
RX.V balance_sheet (annual, 2023-12-31) — Foreign Currency Translation Adjustments: -177455.00
RX.V cash_flow (annual, 2023-12-31) — Free Cash Flow: 4880744.00
RX.V cash_flow (annual, 2023-12-31) — Gain Loss On Investment Securities: 27285.00
RX.V income_statement (annual, 2023-12-31) — Gain On Sale Of Security: -63114.00
RX.V balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: -177455.00
RX.V income_statement (annual, 2023-12-31) — General And Administrative Expense: 9704317.00
RX.V balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 1152876.00
RX.V balance_sheet (annual, 2023-12-31) — Gross PPE: 3323604.00
RX.V income_statement (annual, 2023-12-31) — Gross Profit: 25597943.00
RX.V balance_sheet (annual, 2023-12-31) — Hedging Assets Current: 0.00
RX.V balance_sheet (annual, 2023-12-31) — Held To Maturity Securities: 2500000.00
RX.V income_statement (annual, 2023-12-31) — Impairment Of Capital Assets: 0.00
RX.V cash_flow (annual, 2023-12-31) — Income Tax Paid Supplemental Data: 2414586.00
RX.V balance_sheet (annual, 2023-12-31) — Income Tax Payable: 111114.00
RX.V income_statement (annual, 2023-12-31) — Insurance And Claims: 163328.00
RX.V income_statement (annual, 2023-12-31) — Interest Expense: 68411.00
RX.V income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 68411.00
RX.V income_statement (annual, 2023-12-31) — Interest Income: 1131124.00
RX.V income_statement (annual, 2023-12-31) — Interest Income Non Operating: 1131124.00
RX.V cash_flow (annual, 2023-12-31) — Interest Paid Cff: -68411.00
RX.V cash_flow (annual, 2023-12-31) — Interest Received Cfi: 770703.00
RX.V balance_sheet (annual, 2023-12-31) — Inventory: 5894495.00
RX.V balance_sheet (annual, 2023-12-31) — Invested Capital: 34759756.00
RX.V cash_flow (annual, 2023-12-31) — Investing Cash Flow: 883847.00
RX.V balance_sheet (annual, 2023-12-31) — Investmentin Financial Assets: 2500000.00
RX.V balance_sheet (annual, 2023-12-31) — Investments And Advances: 2500000.00
RX.V balance_sheet (annual, 2023-12-31) — Leases: 680511.00
RX.V balance_sheet (annual, 2023-12-31) — Loans Receivable: 69419.00
RX.V balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 1037731.00
RX.V balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 1037731.00
RX.V cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -174055.00
RX.V balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 1046271.00
RX.V cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: -3068899.00
RX.V income_statement (annual, 2023-12-31) — Net Income: 6460127.00
RX.V income_statement (annual, 2023-12-31) — Net Income Common Stockholders: 6460127.00
RX.V income_statement (annual, 2023-12-31) — Net Income Continuous Operations: 6460127.00
RX.V income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: 6460127.00
RX.V income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: 6460127.00
RX.V cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: 6460127.00
RX.V income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: 6460127.00
RX.V cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: -114704.00
RX.V income_statement (annual, 2023-12-31) — Net Interest Income: 1062713.00
RX.V cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: 128608.00
RX.V cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -174055.00
RX.V cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -174055.00
RX.V income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: 1062713.00
RX.V cash_flow (annual, 2023-12-31) — Net Other Financing Charges: -627192.00
RX.V cash_flow (annual, 2023-12-31) — Net Other Investing Changes: 158766.00
RX.V balance_sheet (annual, 2023-12-31) — Net PPE: 1439930.00
RX.V cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -59526.00
RX.V balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 33606880.00
RX.V balance_sheet (annual, 2023-12-31) — Non Current Deferred Assets: 359470.00
RX.V balance_sheet (annual, 2023-12-31) — Non Current Deferred Liabilities: 197602.00
RX.V balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Assets: 359470.00
RX.V balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Liabilities: 197602.00
RX.V balance_sheet (annual, 2023-12-31) — Non Current Note Receivables: 205182.00
RX.V income_statement (annual, 2023-12-31) — Normalized EBITDA: 9120716.00
RX.V income_statement (annual, 2023-12-31) — Normalized Income: 6507904.30
RX.V cash_flow (annual, 2023-12-31) — Operating Cash Flow: 5054974.00
RX.V cash_flow (annual, 2023-12-31) — Operating Gains Losses: 27285.00
RX.V income_statement (annual, 2023-12-31) — Operating Income: 7534254.00
RX.V income_statement (annual, 2023-12-31) — Operating Revenue: 31590302.00
RX.V balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 11741066.00
RX.V balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 27285.00
RX.V income_statement (annual, 2023-12-31) — Other Gand A: 1560452.00
RX.V income_statement (annual, 2023-12-31) — Other Income Expense: -63114.00
RX.V balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 1152876.00
RX.V cash_flow (annual, 2023-12-31) — Other Non Cash Items: -956714.00
RX.V income_statement (annual, 2023-12-31) — Other Operating Expenses: 117931.00
RX.V balance_sheet (annual, 2023-12-31) — Other Properties: 266367.00
RX.V balance_sheet (annual, 2023-12-31) — Other Receivables: 25329.00
RX.V balance_sheet (annual, 2023-12-31) — Other Short Term Investments: 18202477.00
RX.V balance_sheet (annual, 2023-12-31) — Payables: 5188790.00
RX.V balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 5188790.00
RX.V balance_sheet (annual, 2023-12-31) — Prepaid Assets: 243460.00
RX.V income_statement (annual, 2023-12-31) — Pretax Income: 8533853.00
RX.V cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 66857.00
RX.V balance_sheet (annual, 2023-12-31) — Properties: 0.00
RX.V income_statement (annual, 2023-12-31) — Provision For Doubtful Accounts: 140317.00
RX.V cash_flow (annual, 2023-12-31) — Provisionand Write Offof Assets: 140317.00
RX.V cash_flow (annual, 2023-12-31) — Purchase Of Intangibles: -114704.00
RX.V cash_flow (annual, 2023-12-31) — Purchase Of Investment: -2500000.00
RX.V cash_flow (annual, 2023-12-31) — Purchase Of PPE: -59526.00
RX.V balance_sheet (annual, 2023-12-31) — Raw Materials: 1269980.00
RX.V balance_sheet (annual, 2023-12-31) — Receivables: 3546515.00
RX.V income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 5992359.00
RX.V income_statement (annual, 2023-12-31) — Reconciled Depreciation: 455338.00
RX.V cash_flow (annual, 2023-12-31) — Repayment Of Debt: -174055.00
RX.V cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: -3068899.00
RX.V income_statement (annual, 2023-12-31) — Research And Development: 83271.00
RX.V balance_sheet (annual, 2023-12-31) — Retained Earnings: 27527927.00
RX.V income_statement (annual, 2023-12-31) — Salaries And Wages: 7980537.00
RX.V cash_flow (annual, 2023-12-31) — Sale Of Investment: 2628608.00
RX.V income_statement (annual, 2023-12-31) — Selling And Marketing Expense: 7562515.00
RX.V income_statement (annual, 2023-12-31) — Selling General And Administration: 17266832.00
RX.V balance_sheet (annual, 2023-12-31) — Share Issued: 11954409.00
RX.V income_statement (annual, 2023-12-31) — Special Income Charges: 0.00
RX.V cash_flow (annual, 2023-12-31) — Stock Based Compensation: 513486.00
RX.V balance_sheet (annual, 2023-12-31) — Stockholders Equity: 34759756.00
RX.V balance_sheet (annual, 2023-12-31) — Tangible Book Value: 33606880.00
RX.V income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: -15336.70
RX.V income_statement (annual, 2023-12-31) — Tax Provision: 2073726.00
RX.V income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.24
RX.V balance_sheet (annual, 2023-12-31) — Total Assets: 41528939.00
RX.V balance_sheet (annual, 2023-12-31) — Total Capitalization: 34759756.00
RX.V balance_sheet (annual, 2023-12-31) — Total Debt: 1221045.00
RX.V balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 34759756.00
RX.V income_statement (annual, 2023-12-31) — Total Expenses: 24056048.00
RX.V balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 6769183.00
RX.V balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 5657458.00
RX.V balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 1235333.00
RX.V income_statement (annual, 2023-12-31) — Total Operating Income As Reported: 7471140.00
RX.V balance_sheet (annual, 2023-12-31) — Total Tax Payable: 111114.00
RX.V income_statement (annual, 2023-12-31) — Total Unusual Items: -63114.00
RX.V income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -63114.00
RX.V balance_sheet (annual, 2023-12-31) — Treasury Shares Number: 213343.00
RX.V balance_sheet (annual, 2023-12-31) — Working Capital: 30337631.00
RX.V income_statement (quarterly, 2024-09-30) — Provision For Doubtful Accounts: 0.00
RX.V cash_flow (quarterly, 2024-09-30) — Provisionand Write Offof Assets: 0.00
RX.V cash_flow (quarterly, 2024-09-30) — Purchase Of Investment: -2096209.00
RX.V cash_flow (quarterly, 2024-09-30) — Sale Of Investment: 1325050.00
RX.V income_statement (annual, 2024-12-31) — +Operating Expense: 18791754.00
RX.V income_statement (annual, 2024-12-31) — +Total Revenue: 35030897.00
RX.V balance_sheet (annual, 2024-12-31) — Accounts Payable: 3998938.00
RX.V balance_sheet (annual, 2024-12-31) — Accounts Receivable: 2394929.00
RX.V balance_sheet (annual, 2024-12-31) — Accrued Interest Receivable: 477709.00
RX.V balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -2164894.00
RX.V balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 2139278.00
RX.V income_statement (annual, 2024-12-31) — Amortization: 308728.00
RX.V cash_flow (annual, 2024-12-31) — Amortization Cash Flow: 308728.00
RX.V cash_flow (annual, 2024-12-31) — Amortization Of Intangibles: 308728.00
RX.V income_statement (annual, 2024-12-31) — Amortization Of Intangibles Income Statement: 308728.00
RX.V cash_flow (annual, 2024-12-31) — Asset Impairment Charge: 430016.00
RX.V income_statement (annual, 2024-12-31) — Basic Average Shares: 11282017.00
RX.V income_statement (annual, 2024-12-31) — Basic EPS: 0.64
RX.V cash_flow (annual, 2024-12-31) — Beginning Cash Position: 7984534.00
RX.V balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 1330455.00
RX.V cash_flow (annual, 2024-12-31) — Capital Expenditure: -4669651.00
RX.V balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 1037731.00
RX.V balance_sheet (annual, 2024-12-31) — Capital Stock: 5306450.00
RX.V balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 12113376.00
RX.V balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 15940971.00
RX.V cash_flow (annual, 2024-12-31) — Cash Dividends Paid: -2079691.00
RX.V balance_sheet (annual, 2024-12-31) — Cash Equivalents: 2491426.00
RX.V balance_sheet (annual, 2024-12-31) — Cash Financial: 9621950.00
RX.V cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: -7828563.00
RX.V cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: 3288020.00
RX.V cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: 8663484.00
RX.V cash_flow (annual, 2024-12-31) — Change In Account Payable: -1078738.00
RX.V cash_flow (annual, 2024-12-31) — Change In Income Tax Payable: 285229.00
RX.V cash_flow (annual, 2024-12-31) — Change In Inventory: 566409.00
RX.V cash_flow (annual, 2024-12-31) — Change In Other Working Capital: 678737.00
RX.V cash_flow (annual, 2024-12-31) — Change In Payable: -793509.00
RX.V cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: -793509.00
RX.V cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: 41489.00
RX.V cash_flow (annual, 2024-12-31) — Change In Receivables: 395318.00
RX.V cash_flow (annual, 2024-12-31) — Change In Tax Payable: 285229.00
RX.V cash_flow (annual, 2024-12-31) — Change In Working Capital: 888444.00
RX.V cash_flow (annual, 2024-12-31) — Changes In Cash: 4122941.00
RX.V balance_sheet (annual, 2024-12-31) — Common Stock: 5306450.00
RX.V cash_flow (annual, 2024-12-31) — Common Stock Dividend Paid: -2079691.00
RX.V cash_flow (quarterly, 2024-12-31) — Common Stock Dividend Paid: -512891.00
RX.V balance_sheet (annual, 2024-12-31) — Common Stock Equity: 35003185.00
RX.V cash_flow (annual, 2024-12-31) — Common Stock Payments: -5176660.00
RX.V income_statement (annual, 2024-12-31) — Cost Of Revenue: 7174824.00
RX.V balance_sheet (annual, 2024-12-31) — Current Assets: 24471080.00
RX.V balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 196627.00
RX.V balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 196627.00
RX.V balance_sheet (annual, 2024-12-31) — Current Deferred Liabilities: 813198.00
RX.V balance_sheet (annual, 2024-12-31) — Current Deferred Revenue: 813198.00
RX.V balance_sheet (annual, 2024-12-31) — Current Liabilities: 5405106.00
RX.V cash_flow (annual, 2024-12-31) — Deferred Income Tax: -129243.00
RX.V cash_flow (annual, 2024-12-31) — Deferred Tax: -129243.00
RX.V cash_flow (annual, 2024-12-31) — Depreciation: 281220.00
RX.V cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 589948.00
RX.V income_statement (annual, 2024-12-31) — Depreciation Amortization Depletion Income Statement: 589948.00
RX.V cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 589948.00
RX.V income_statement (annual, 2024-12-31) — Depreciation And Amortization In Income Statement: 589948.00
RX.V income_statement (annual, 2024-12-31) — Depreciation Income Statement: 281220.00
RX.V income_statement (annual, 2024-12-31) — Diluted Average Shares: 11282017.00
RX.V income_statement (annual, 2024-12-31) — Diluted EPS: 0.64
RX.V income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: 7270104.00
RX.V income_statement (annual, 2024-12-31) — EBIT: 9841650.00
RX.V income_statement (annual, 2024-12-31) — EBITDA: 10431598.00
RX.V cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: 5901.00
RX.V cash_flow (annual, 2024-12-31) — End Cash Position: 12113376.00
RX.V cash_flow (annual, 2024-12-31) — Financing Cash Flow: -7828563.00
RX.V balance_sheet (annual, 2024-12-31) — Finished Goods: 4346833.00
RX.V balance_sheet (annual, 2024-12-31) — Foreign Currency Translation Adjustments: -171554.00
RX.V cash_flow (annual, 2024-12-31) — Free Cash Flow: 3993833.00
RX.V cash_flow (annual, 2024-12-31) — Gain Loss On Investment Securities: -33075.00
RX.V income_statement (annual, 2024-12-31) — Gain On Sale Of Security: 118761.00
RX.V balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: -171554.00
RX.V income_statement (annual, 2024-12-31) — General And Administrative Expense: 10793455.00
RX.V balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 5041501.00
RX.V balance_sheet (annual, 2024-12-31) — Gross PPE: 3365886.00
RX.V income_statement (annual, 2024-12-31) — Gross Profit: 27856073.00
RX.V balance_sheet (annual, 2024-12-31) — Hedging Assets Current: 5790.00
RX.V balance_sheet (annual, 2024-12-31) — Held To Maturity Securities: 10103571.00
RX.V income_statement (annual, 2024-12-31) — Impairment Of Capital Assets: 430016.00
RX.V cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 2356408.00
RX.V balance_sheet (annual, 2024-12-31) — Income Tax Payable: 396343.00
RX.V income_statement (annual, 2024-12-31) — Insurance And Claims: 203527.00
RX.V income_statement (annual, 2024-12-31) — Interest Expense: 59152.00
RX.V income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 59152.00
RX.V income_statement (annual, 2024-12-31) — Interest Income: 1088586.00
RX.V income_statement (annual, 2024-12-31) — Interest Income Non Operating: 1088586.00
RX.V cash_flow (annual, 2024-12-31) — Interest Paid Cff: -59152.00
RX.V cash_flow (annual, 2024-12-31) — Interest Received Cfi: 1127044.00
RX.V balance_sheet (annual, 2024-12-31) — Inventory: 5328086.00
RX.V balance_sheet (annual, 2024-12-31) — Invested Capital: 35003185.00
RX.V cash_flow (annual, 2024-12-31) — Investing Cash Flow: 3288020.00
RX.V balance_sheet (annual, 2024-12-31) — Investmentin Financial Assets: 10103571.00
RX.V balance_sheet (annual, 2024-12-31) — Investments And Advances: 10103571.00
RX.V balance_sheet (annual, 2024-12-31) — Leases: 680511.00
RX.V balance_sheet (annual, 2024-12-31) — Loans Receivable: 87433.00
RX.V balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 841104.00
RX.V balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 841104.00
RX.V cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -183314.00
RX.V balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 1088553.00
RX.V cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: -5176660.00
RX.V income_statement (annual, 2024-12-31) — Net Income: 7270104.00
RX.V income_statement (annual, 2024-12-31) — Net Income Common Stockholders: 7270104.00
RX.V income_statement (annual, 2024-12-31) — Net Income Continuous Operations: 7270104.00
RX.V income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 7270104.00
RX.V income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 7270104.00
RX.V cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: 7270104.00
RX.V income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: 7270104.00
RX.V cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: -4627369.00
RX.V income_statement (annual, 2024-12-31) — Net Interest Income: 1029434.00
RX.V cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: 6771311.00
RX.V cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -183314.00
RX.V cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -183314.00
RX.V income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 1029434.00
RX.V cash_flow (annual, 2024-12-31) — Net Other Financing Charges: -580134.00
RX.V cash_flow (annual, 2024-12-31) — Net Other Investing Changes: 59316.00
RX.V balance_sheet (annual, 2024-12-31) — Net PPE: 1200992.00